Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment

Topic This systematic review and meta-analysis provides a summary of the efficacy safety ranibizumab biosimilars relative to reference anti-vascular endothelial growth factor (VEGF) therapy for treatment neovascular age-related macular degeneration (nAMD). Methods We conducted searches from January 2003 August 2022 on Ovid MEDLINE, EMBASE Cochrane Controlled Register Trials. included studies reporting changes in early diabetic retinopathy study-measured best-corrected visual acuity (BCVA), number patients who lost or gained more than 15 letters BCVA baseline, retinal thickness adverse events between arms. The following were excluded: that did not report outcomes biosimilar intravitreal injections, study arms combining anti-VEGF agents with laser steroid sham injections as control comparator, without English full texts non-comparative, observational design. Results Five reported four randomised controlled trials (RCTs) 1544 eyes at baseline this meta-analysis. our found no significant differences medications (FYB201, SB11, RanizuRel Lupin’s ranibizumab) anatomical outcomes. No detected emergent (risk ratio, RR 1.06, 95% CI (0.91 1.23), p=0.45, I 2 =52%) IOP-related heterogeneity (RR 2.59, (0.11 62.25), p=0.56, =76%). Conclusion RCTs demonstrated difference outcomes, well therapies nAMD treatment.